Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of Infliximab Biosimilar in Treatment of Moderate to Severe Psoriasis; A Single-arm Clinical Trial
Sponsor: Services Institute of Medical Sciences, Pakistan
Summary
The goal of this clinical trial is to learn if Infliximab Biosimilar Remsima works to treat moderate to severe plaque Psoriasis in adults. It will also learn about the safety of the drug. The main questions it aims to answer are: Does Infliximab-dyyb Biosimilar (Remsima) works to treat moderate to severe plaque Psoriasis in adults in reducing disease severity and relapses? What medical problems do participants have when taking Remsima? Participants will: be injected Infliximab Biosimilar Remsima weekly for 4 weeks and then fortnightly till 24 weeks They will be followed for efficacy and safety and lab tests at week 4, 14, 24 and 52.
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
104
Start Date
2023-11-06
Completion Date
2024-11-05
Last Updated
2024-09-19
Healthy Volunteers
No
Interventions
Infliximab-dyyb Biosimilar (Remsima)
Subcutaneous injections of Infliximab-dyyb Biosimilar (Remsima) were injected weekly for 4 weeks and then fortnightly for 24 weeks
Locations (1)
Department of Dermatology, Services Institute of Medical Sciences/ Services Hospital
Lahore, Punjab Province, Pakistan